



CONTACT: David Sheon
dsheon@WhitecoatStrategies.com
202 422-6999

FOR IMMEDIATE RELEASE

New Research Shows Gazelle Diagnostic Device Outperformed Rapid Diagnostic Test for *P. Vivax* Malaria, Detected Challenging Types of Malaria, and Provided Accurate Sickle Cell Disease Detection

Researchers to Present Five Scientific Posters at the 2020 American Society of Tropical Medicine and Hygiene Annual Meeting

Portland, Ore. [November 15, 2020] – Hemex Health, an innovator in point-of-care diagnostic technologies, announced today that researchers will present five scientific posters at the 2020 American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting showcasing the company’s Gazelle® platform – a novel approach to identifying malaria and sickle cell disease accurately within minutes.

Gazelle is a compact, rugged, battery-operated diagnostic device. Gazelle can be used inexpensively, with no cold chain requirements by entry level healthcare workers in areas with limited access, resources or electricity. Patient information and results are captured digitally for storage, printing, or later transmission to the cloud.

“Gazelle has a unique approach that uses hemozoin to find malaria accurately in about one minute,” said Patti White, co-founder and CEO of Hemex Health. “This research shows that when Gazelle was tested in the field, it accurately and quickly found malaria species that were not successfully identified by rapid diagnostic tests.”

Below are highlights of the clinical information supporting Gazelle that will be given at the 2020 ASTMH Annual Meeting:

Title: Gazelle: A portable point-of-care diagnostic with high accuracy and fast turnaround time for detecting *P. vivax* malaria

A study conducted in the Brazilian Amazon on *P. vivax* showed that Gazelle was more sensitive than RDTs and comparable in accuracy to expert microscopy, but significantly faster than RDTs, microscopy and PCR.

Title: New diagnostic demonstrates improved limit of detection for *P. vivax* in multi-site testing

Research demonstrated that Gazelle had over 6x lower limit of detection for *P. vivax* malaria than RDTs when evaluated in dilution testing in Cambodia, Brazil, and India.

Title: Gazelle: Evaluation of a novel point-of-care haemozoin assay (Gazelle™) for rapid detection of *Plasmodium knowlesi* malaria in Sabah, East Malaysia

Researchers in Malaysia are evaluating Gazelle's ability to detect *P. knowlesi*. *P. knowlesi* is a malaria-causing parasite which is difficult to detect by RDTs and is the main cause of human malaria in Malaysia. Results from the pilot phase of this study that included 40 positive patients indicated that Gazelle was 95% sensitive for finding *P. knowlesi*. Gazelle is also much faster and easier to use than microscopy, which is the primary malaria detection method in Malaysia.

Title: Using Gazelle Hemozoin based Malaria Diagnostic to differentiate between Plasmodium Species

This poster demonstrates Gazelle's methodology for differentiating between *P. falciparum*, *P. vivax*, and *P. knowlesi* using hemozoin properties. A large-scale study in India is planned to validate the methodology.

Title: Field evaluation of microchip-based point-of-care device 'Gazelle' for diagnosis of haemoglobin disorders in India

Researchers at India's National Institute of Research in Tribal Health (NIRTH) tested the performance of Gazelle in detecting sickle cell disease and trait. When compared to standard diagnostic methods in this 949-patient study, Gazelle was not only highly sensitive and specific in identifying the disease, but also is much faster, less expensive and requires less training than currently used test methods.

About Hemex Health and the Gazelle Diagnostic Device

Hemex Health breaks traditional barriers with its innovative diagnostic system that expands the reach of diagnostics to new emerging diseases, new locations, and new populations.

The company's Gazelle® diagnostic platform, approved for detecting malaria and sickle cell disease in a growing list of countries, includes miniaturized versions of trusted technologies, innovative optics, and artificial intelligence. This versatile approach allows the company to continually add diseases to its menu of tests and expand to new users. Gazelle is an accurate and rapid digital platform that can work just about anywhere in the world. With its affordable, compact, and rugged design, and all-day battery power, it delivers powerful diagnostics to more places without the need for a cold chain-- from remote, low-resource settings, to drive through testing, border crossings, or nursing homes.

Hemex Health designs diagnostic technologies for the real world by listening to the needs of healthcare providers including in some of the most remote and challenging settings. The

Gazelle technology was developed in collaboration with Case Western Reserve University. Hemex Health is located in Portland, Oregon, USA. HemexDx, a subsidiary of Hemex Health, is located in Mumbai, India. More information can be found by going to www.hemexhealth.com.

###